Sandbox:FF: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 6: Line 6:


==Overview==
==Overview==
''Candida auris'' is a fungus, recently described as a rare cause of fungal infection with significant resistance to [[antifungal medications]].<ref name="pmidPMID 24357342">{{cite journal| author=Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R et al.| title=Multidrug-resistant endemic clonal strain of Candida auris in India. | journal=Eur J Clin Microbiol Infect Dis | year= 2014 | volume= 33 | issue= 6 | pages= 919-26 | pmid=PMID 24357342 | doi=10.1007/s10096-013-2027-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24357342  }} </ref> It was first described in the year 2009 in Japan,<ref name="pmidPMID 27832049">{{cite journal| author=Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J et al.| title=Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016. | journal=MMWR Morb Mortal Wkly Rep | year= 2016 | volume= 65 | issue= 44 | pages= 1234-1237 | pmid=PMID 27832049 | doi=10.15585/mmwr.mm6544e1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27832049  }} </ref> and since then, reports of ''C. auris'' infection has been published from several countries.<ref name="pmidPMID 27832049" /> Serious and prolonged outbreaks have been documented with data showing an innate resilience of ''C.auris'' for survival, persistence in the clinical environment with the ability to rapidly colonize patient's skin, and high transmissibility within the healthcare system.<sup>[[Sandbox:FB|[4]]]</sup> The precise mode of transmission within the healthcare facility is unknown.<ref name="cdc1">Centers for Disease Control and Prevention. https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html Accessed on November 11th, 2016. </ref><ref name=cdc2>Public Health England.https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/534174/Guidance_Candida__auris.pdf. Accessed on November 11th, 2016.</ref> The high rate of therapeutic failure noted in cases of ''Candida auris'' fungemia poses significant concerns.<ref name="pmidPMID 24357342" /> Misidentification of ''C.auris'' with related ''[[Candida]]'' species such as ''Candida haemulonii'' by commercially available biochemical-based tests poses a challenge.<ref name="cdc1" /> ''C. auris'' is recognized as a globally emerging fungal pathogen.<ref name="pmidPMID 26548511">{{cite journal| author=Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F et al.| title=Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. | journal=Clin Microbiol Infect | year= 2016 | volume= 22 | issue= 3 | pages= 277.e1-9 | pmid=PMID 26548511 | doi=10.1016/j.cmi.2015.10.022 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26548511  }} </ref><ref name="pmidPMID 27777756">{{cite journal| author=Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A et al.| title=First hospital outbreak of the globally emerging Candida auris in a European hospital. | journal=Antimicrob Resist Infect Control | year= 2016 | volume= 5 | issue=  | pages= 35 | pmid=PMID 27777756 | doi=10.1186/s13756-016-0132-5 | pmc=5069812 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27777756  }} </ref> Institution of key infection prevention and control measures<ref name="cdc2" /> and, correct identification and standardized antifungal susceptibility testing for optimal management strategies of patients with invasive infections can hardly be overemphasized.<ref name="cdc2" />
''Candida auris'' is a fungus, recently described as a rare cause of fungal infection with significant resistance to [[antifungal medications]].<ref name="pmidPMID 24357342">{{cite journal| author=Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R et al.| title=Multidrug-resistant endemic clonal strain of Candida auris in India. | journal=Eur J Clin Microbiol Infect Dis | year= 2014 | volume= 33 | issue= 6 | pages= 919-26 | pmid=PMID 24357342 | doi=10.1007/s10096-013-2027-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24357342  }} </ref> It was first described in the year 2009 in Japan,<ref name="pmidPMID 27832049">{{cite journal| author=Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J et al.| title=Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016. | journal=MMWR Morb Mortal Wkly Rep | year= 2016 | volume= 65 | issue= 44 | pages= 1234-1237 | pmid=PMID 27832049 | doi=10.15585/mmwr.mm6544e1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27832049  }} </ref> and since then, reports of ''C. auris'' infection has been published from several countries.<ref name="pmidPMID 27832049" /> However, retrospective testing of collected isolates show the earliest known infection with C. auris occurred in South Korea in 1996. Serious and prolonged outbreaks have been documented with data showing an innate resilience of ''C.auris'' for survival, persistence in the clinical environment with the ability to rapidly colonize patient's skin, and high transmissibility within the healthcare system.<sup>[[Sandbox:FB|[4]]]</sup> The precise mode of transmission within the healthcare facility is unknown.<ref name="cdc1">Centers for Disease Control and Prevention. https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html Accessed on November 11th, 2016. </ref><ref name=cdc2>Public Health England.https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/534174/Guidance_Candida__auris.pdf. Accessed on November 11th, 2016.</ref> The high rate of therapeutic failure noted in cases of ''Candida auris'' fungemia poses significant concerns.<ref name="pmidPMID 24357342" /> Misidentification of ''C.auris'' with related ''[[Candida]]'' species such as ''Candida haemulonii'' by commercially available biochemical-based tests poses a challenge.<ref name="cdc1" /> ''C. auris'' is recognized as a globally emerging fungal pathogen.<ref name="pmidPMID 26548511">{{cite journal| author=Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F et al.| title=Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. | journal=Clin Microbiol Infect | year= 2016 | volume= 22 | issue= 3 | pages= 277.e1-9 | pmid=PMID 26548511 | doi=10.1016/j.cmi.2015.10.022 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26548511  }} </ref><ref name="pmidPMID 27777756">{{cite journal| author=Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A et al.| title=First hospital outbreak of the globally emerging Candida auris in a European hospital. | journal=Antimicrob Resist Infect Control | year= 2016 | volume= 5 | issue=  | pages= 35 | pmid=PMID 27777756 | doi=10.1186/s13756-016-0132-5 | pmc=5069812 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27777756  }} </ref> Institution of key infection prevention and control measures<ref name="cdc2" /> and, correct identification and standardized antifungal susceptibility testing for optimal management strategies of patients with invasive infections can hardly be overemphasized.<ref name="cdc2" />
==Historical Perspective==
==Historical Perspective==
* ''C. auris'' was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan.<ref name="pmidPMID 27832049" />
* ''C. auris'' was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan.<ref name="pmidPMID 27832049" />
Line 34: Line 34:
==Infection==
==Infection==
* ''C. auris'' is a novel ascomycetous yeast species belonging to the genus ''Candida.''<ref name="pmid19161556">{{cite journal| author=Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H| title=Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. | journal=Microbiol Immunol | year= 2009 | volume= 53 | issue= 1 | pages= 41-4 | pmid=19161556 | doi=10.1111/j.1348-0421.2008.00083.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19161556  }} </ref>  
* ''C. auris'' is a novel ascomycetous yeast species belonging to the genus ''Candida.''<ref name="pmid19161556">{{cite journal| author=Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H| title=Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. | journal=Microbiol Immunol | year= 2009 | volume= 53 | issue= 1 | pages= 41-4 | pmid=19161556 | doi=10.1111/j.1348-0421.2008.00083.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19161556  }} </ref>  
* It can cause invasive infections, and it is associated with high mortality.<ref name="pmidPMID 27832049" />
 
* ''C. auris'' cases have been identified from clinical sites such as wound swabs, urine samples, vascular devices tips, blood cultures as well as skin screening samples (including nose, oropharynx, axilla, groin and stool samples).<ref name="pmidPMID 27777756" />
* ''C. auris'' cases have been identified from clinical sites such as wound swabs, urine samples, vascular devices tips, blood cultures as well as skin screening samples (including nose, oropharynx, axilla, groin and stool samples).<ref name="pmidPMID 27777756" />
* ''C. auris'' has been reported to cause bloodstream infections, wound infections, and [[otitis]].<ref name="cdc1" /><ref name="pmid21715586" />
* ''C. auris'' has been reported to cause bloodstream infections, wound infections, and [[otitis]].<ref name="cdc1" /><ref name="pmid21715586" />
Line 122: Line 122:


=== Prognosis ===
=== Prognosis ===
* It can cause invasive infections, and it is associated with high mortality.<ref name="pmidPMID 27832049" />
* [[Candidemia]]  attributed to ''C auris'' is associated with mortality of up to 50 % in some countries.<ref name="pmidPMID 27777756" />
* [[Candidemia]]  attributed to ''C auris'' is associated with mortality of up to 50 % in some countries.<ref name="pmidPMID 27777756" />


Revision as of 21:39, 14 November 2016


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fatimo Biobaku M.B.B.S [2]

This page is describing the Candida auris infection. For more information on the microorganism click here.

Overview

Candida auris is a fungus, recently described as a rare cause of fungal infection with significant resistance to antifungal medications.[1] It was first described in the year 2009 in Japan,[2] and since then, reports of C. auris infection has been published from several countries.[2] However, retrospective testing of collected isolates show the earliest known infection with C. auris occurred in South Korea in 1996. Serious and prolonged outbreaks have been documented with data showing an innate resilience of C.auris for survival, persistence in the clinical environment with the ability to rapidly colonize patient's skin, and high transmissibility within the healthcare system.[4] The precise mode of transmission within the healthcare facility is unknown.[3][4] The high rate of therapeutic failure noted in cases of Candida auris fungemia poses significant concerns.[1] Misidentification of C.auris with related Candida species such as Candida haemulonii by commercially available biochemical-based tests poses a challenge.[3] C. auris is recognized as a globally emerging fungal pathogen.[5][6] Institution of key infection prevention and control measures[4] and, correct identification and standardized antifungal susceptibility testing for optimal management strategies of patients with invasive infections can hardly be overemphasized.[4]

Historical Perspective

  • C. auris was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan.[2]
  • C. auris was incidentally found by molecular identification of bloodstream isolates of unidentified yeasts recovered in 1996, suggesting the paucity of isolation of C. auris may partly reflect the difficulty in identifying the specie.[7]
  • The occurrence of C. auris in nine countries on four continents since 2009 has been reported.[3]
  • C. auris infections have most commonly been hospital-acquired and occurred several weeks into a patient’s hospital stay.[3]
  • It has been documented to cause infections in patients of all ages.[3][7][8]

Causes

Pathophysiology

Pathogenesis

  • High potential for nosocomial horizontal transmission.[6][9]
  • The exact mode of transmission is unknown.[3][4]


Genetics

Microscopic Pathology

Gross Pathology

Associated Conditions

Infection

  • C. auris is a novel ascomycetous yeast species belonging to the genus Candida.[10]
  • C. auris cases have been identified from clinical sites such as wound swabs, urine samples, vascular devices tips, blood cultures as well as skin screening samples (including nose, oropharynx, axilla, groin and stool samples).[6]
  • C. auris has been reported to cause bloodstream infections, wound infections, and otitis.[3][7]
  • Stay in the Intensive Care Unit has been reported as a major risk factor for C. auris infection.[6]
  • Patients were found to have similar risk factors for infection with other Candida spp.[3]
  • The occurrence of candidemia attributed to C. auris appears increasingly common.[6]
  • Evidence of distinct geographic clustering of Candida auris isolates has been established.[5]

Differentiating Candida auris from other Candida species

  • C. auris, on microscopy, is indistinguishable from most other Candida species.[4] It is a germ tube test negative budding yeast, however some strains can form rudimentary pseudohyphae on cornmeal agar. Most C. auris isolates are a pale purple or pink colour on the chromogenic agar (CHROMagar), in common with several other non C. albicans species. Growth on this and other chromogenic agars (which may display a different colour) cannot be used as a primary identification method. Chromogenic agars are useful to identify mixed cultures including the presence of C. albicans. If there is evidence of non - albicans on chromogenic agar these should be sub-cultured on Sabouraud’s agar and identified according to local laboratory protocols.[4]
  • It is unlikely that any of the currently available biochemical-based tests will include C. auris in their database as it is a newly recognised species so laboratories are advised to check the databases provided for their current methods. According to published data, commercially available biochemical-based tests, including API AUX 20C and VITEK-2 YST, used in many front line diagnostic laboratories can misidentify C. auris as Candida haemulonii, Saccharomyces cerevisiae. Therefore, it is important that any Candida spp isolates associated with invasive infections and isolates from superficial sites in patients from high intensity settings and those transferred from an affected hospital should be analysed to species level. If Candida haemulonii, Candida famata, Candida sake or Saccharomyces cerevisiae are identified, further work should be undertaken to ensure that they are not C. auris. This would involve either molecular sequencing of the D1/D2 domain or MALDI-TOF(matrix-assisted laser desorption ionization time-of-flight mass spectrometry) Biotyper analysis with C. auris either already present or added to the database.[4]

Epidemiology and Demographics

Prevalence

Incidence

Age

Gender

Race

Geographical Distribution

Country/Region First Reported Case Reported Cases Presentation Reported Cases
Japan 2009 45 Fever and Fungemia 30
2015
United States November 2016

C. auris was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan.[2] Since then, reports of C. auris infections, including bloodstream infections, have been published from several countries, including Colombia, India, Israel, Kenya, Kuwait, Pakistan, South Africa, South Korea, Venezuela, and the United Kingdom.[2] Seven cases have been described in the US.[2]

Pediatric and adult cases of Candida auris fungemia have been documented.[3][7][8]

Risk factors

  • Patients who had a prolonged hospital stay.[3]
  • Patients were found to have similar risk factors for infections with other Candida spp including diabetes mellitus, recent surgery, recent antibiotics, and presence of central venous catheters.[3]
  • Co-infection with other Candida spp.[3]
  • C. auris detection while the patient was being treated with antifungals have also been reported.[3]

Screening

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

  • It can cause invasive infections, and it is associated with high mortality.[2]
  • Candidemia attributed to C auris is associated with mortality of up to 50 % in some countries.[6]

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

  • Currently, reliable methods for speciation are molecular based methods such as PCR, AFLP(amplified fragment length polymorphism) fingerprinting, sequencing analysis, and MALDI-TOF biotyping.[4][6]

Treatment

Medical Therapy

  • Early identification of Candida species.[6]
  • Candida auris isolates from north and south Indian hospitals, Japan and Korea were all found to be resistant to the antifungal medication fluconazole.[1]Some isolates were also noted to be resistant to antifungal medications such as flucytosine and voriconazole.[1]
  • Antifungal susceptibility testing: There are no established minimum inhibitory concentration (MIC) breakpoints at present for C. auris. Using breakpoints for other Candida spp, the Centers for Disease Control and Prevention (CDC) demonstrated that of the global outbreaks that they have been investigating, nearly all isolates are highly resistant to fluconazole. In their analysis, more than half of C. auris isolates were resistant to voriconazole, one- third were resistant to amphotericin B (MIC ≥2 mg/L), and a few were resistant to echinocandins. Some isolates have demonstrated elevated MICs to all three major antifungal classes, including azoles, echinocandins, and polyenes indicating that treatment options would be limited. Whole genome sequencing of the organism has found resistant determinants to a variety of antifungal agents.[4]
  • First-line therapy remains an echinocandin pending specific susceptibility testing which should be undertaken as soon as possible. However, there is evidence that resistance can evolve quite rapidly in this species, ongoing vigilance for evolving resistance is advised in patients who are found to be infected or colonised with C. auris. There is currently no evidence or experience to support combination therapy in invasive infections with this organism and clinicians are advised to make decisions on a case by case basis.[4]





Surgery

Primary Prevention

  • isolation of colonized or infected patients with en suite facilities wherever possible.[4]
  • Adherence to strict Infection Prevention and Control precautions, including hand hygiene using soap and water followed by alcohol hand rub, use of personal protective equipment in the form of gloves and aprons (or gowns if there is a high risk of soiling with blood or body fluids).[4]
  • A chlorine releasing agent is currently recommended for cleaning of the environment at 1000 ppm of available chlorine.[4]
  • A terminal clean should be undertaken once the patient has left the environment preferably using hydrogen peroxide vapour. All equipment should be cleaned in accordance with manufacturer’s instructions and where relevant, returned to the company for cleaning. Particular attention should be paid to cleaning of multiple-use equipment (such as BP cuffs, thermometers, computers on wheels, ultra-sound machines) from the bed spaces of infected/colonized patient.[4]




Secondary Prevention

References

  1. ↑ 1.0 1.1 1.2 1.3 Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R; et al. (2014). "Multidrug-resistant endemic clonal strain of Candida auris in India". Eur J Clin Microbiol Infect Dis. 33 (6): 919–26. doi:10.1007/s10096-013-2027-1. PMID 24357342 PMID 24357342 Check |pmid= value (help).
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J; et al. (2016). "Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016". MMWR Morb Mortal Wkly Rep. 65 (44): 1234–1237. doi:10.15585/mmwr.mm6544e1. PMID 27832049 PMID 27832049 Check |pmid= value (help).
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 Centers for Disease Control and Prevention. https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html Accessed on November 11th, 2016.
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 Public Health England.https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/534174/Guidance_Candida__auris.pdf. Accessed on November 11th, 2016.
  5. ↑ 5.0 5.1 Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F; et al. (2016). "Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism". Clin Microbiol Infect. 22 (3): 277.e1–9. doi:10.1016/j.cmi.2015.10.022. PMID 26548511 PMID 26548511 Check |pmid= value (help).
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A; et al. (2016). "First hospital outbreak of the globally emerging Candida auris in a European hospital". Antimicrob Resist Infect Control. 5: 35. doi:10.1186/s13756-016-0132-5. PMC 5069812. PMID 27777756 PMID 27777756 Check |pmid= value (help).
  7. ↑ 7.0 7.1 7.2 7.3 Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH; et al. (2011). "First three reported cases of nosocomial fungemia caused by Candida auris". J Clin Microbiol. 49 (9): 3139–42. doi:10.1128/JCM.00319-11. PMC 3165631. PMID 21715586.
  8. ↑ 8.0 8.1 Emara M, Ahmad S, Khan Z, Joseph L, Al-Obaid I, Purohit P; et al. (2015). "Candida auris candidemia in Kuwait, 2014". Emerg Infect Dis. 21 (6): 1091–2. doi:10.3201/eid2106.150270. PMC 4451886. PMID 25989098 PMID 25989098 Check |pmid= value (help).
  9. ↑ Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F; et al. (2016). "First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia". J Infect. 73 (4): 369–74. doi:10.1016/j.jinf.2016.07.008. PMID 27452195 PMID 27452195 Check |pmid= value (help).
  10. ↑ Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H (2009). "Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital". Microbiol Immunol. 53 (1): 41–4. doi:10.1111/j.1348-0421.2008.00083.x. PMID 19161556.

WikiDoc Resources for Sandbox:FF

Articles

Most recent articles on Sandbox:FF

Most cited articles on Sandbox:FF

Review articles on Sandbox:FF

Articles on Sandbox:FF in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Sandbox:FF

Images of Sandbox:FF

Photos of Sandbox:FF

Podcasts & MP3s on Sandbox:FF

Videos on Sandbox:FF

Evidence Based Medicine

Cochrane Collaboration on Sandbox:FF

Bandolier on Sandbox:FF

TRIP on Sandbox:FF

Clinical Trials

Ongoing Trials on Sandbox:FF at Clinical Trials.gov

Trial results on Sandbox:FF

Clinical Trials on Sandbox:FF at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sandbox:FF

NICE Guidance on Sandbox:FF

NHS PRODIGY Guidance

FDA on Sandbox:FF

CDC on Sandbox:FF

Books

Books on Sandbox:FF

News

Sandbox:FF in the news

Be alerted to news on Sandbox:FF

News trends on Sandbox:FF

Commentary

Blogs on Sandbox:FF

Definitions

Definitions of Sandbox:FF

Patient Resources / Community

Patient resources on Sandbox:FF

Discussion groups on Sandbox:FF

Patient Handouts on Sandbox:FF

Directions to Hospitals Treating Sandbox:FF

Risk calculators and risk factors for Sandbox:FF

Healthcare Provider Resources

Symptoms of Sandbox:FF

Causes & Risk Factors for Sandbox:FF

Diagnostic studies for Sandbox:FF

Treatment of Sandbox:FF

Continuing Medical Education (CME)

CME Programs on Sandbox:FF

International

Sandbox:FF en Espanol

Sandbox:FF en Francais

Business

Sandbox:FF in the Marketplace

Patents on Sandbox:FF

Experimental / Informatics

List of terms related to Sandbox:FF

Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:FF&oldid=1270171"